← 產業報告目錄
Liposomal Amphoteracin B Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 106報告編號 APO-d0f336cdef
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Liposomal Amphoteracin B market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Liposomal Amphoteracin B is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Liposomal Amphoteracin B is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Liposomal Amphoteracin B is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Liposomal Amphoteracin B include Gilead Sciences and Cipla among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Liposomal Amphoteracin B market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liposomal Amphoteracin B Market by Company
Gilead Sciences
Cipla
Liposomal Amphoteracin B Segment by Type
25mg
50mg
Liposomal Amphoteracin B Segment by Application
Hospital
Pharmacy
Liposomal Amphoteracin B Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal Amphoteracin B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomal Amphoteracin B and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal Amphoteracin B.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Liposomal Amphoteracin B manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Liposomal Amphoteracin B by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Liposomal Amphoteracin B in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Liposomal Amphoteracin B Market Size (2021-2032)
2.2.2 Global Liposomal Amphoteracin B Sales (2021-2032)
2.2.3 Global Liposomal Amphoteracin B Market Average Price (2021-2032)
2.3 Liposomal Amphoteracin B by Type
2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
2.3.2 25mg
2.3.3 50mg
2.4 Liposomal Amphoteracin B by Application
2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.4.2 Hospital
2.4.3 Pharmacy
3 Market Competitive Landscape by Manufacturers
3.1 Global Liposomal Amphoteracin B Market Competitive Situation by Manufacturers (2021 Versus 2025)
3.2 Global Liposomal Amphoteracin B Sales (K Units) of Manufacturers (2021-2026)
3.3 Global Liposomal Amphoteracin B Revenue of Manufacturers (2021-2026)
3.4 Global Liposomal Amphoteracin B Average Price by Manufacturers (2021-2026)
3.5 Global Liposomal Amphoteracin B Industry Ranking, 2024 VS 2025 VS 2026
3.6 Global Manufacturers of Liposomal Amphoteracin B, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Liposomal Amphoteracin B, Product Type & Application
3.8 Global Manufacturers of Liposomal Amphoteracin B, Established Date
3.9 Global Liposomal Amphoteracin B Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Gilead Sciences
4.1.1 Gilead Sciences Company Information
4.1.2 Gilead Sciences Business Overview
4.1.3 Gilead Sciences Liposomal Amphoteracin B Sales, Revenue and Gross Margin (2021-2026)
4.1.4 Gilead Sciences Liposomal Amphoteracin B Product Portfolio
4.1.5 Gilead Sciences Recent Developments
4.2 Cipla
4.2.1 Cipla Company Information
4.2.2 Cipla Business Overview
4.2.3 Cipla Liposomal Amphoteracin B Sales, Revenue and Gross Margin (2021-2026)
4.2.4 Cipla Liposomal Amphoteracin B Product Portfolio
4.2.5 Cipla Recent Developments
5 Global Liposomal Amphoteracin B Market Scenario by Region
5.1 Global Liposomal Amphoteracin B Market Size by Region: 2021 VS 2025 VS 2032
5.2 Global Liposomal Amphoteracin B Sales by Region: 2021-2032
5.2.1 Global Liposomal Amphoteracin B Sales by Region: 2021-2026
5.2.2 Global Liposomal Amphoteracin B Sales by Region: 2027-2032
5.3 Global Liposomal Amphoteracin B Revenue by Region: 2021-2032
5.3.1 Global Liposomal Amphoteracin B Revenue by Region: 2021-2026
5.3.2 Global Liposomal Amphoteracin B Revenue by Region: 2027-2032
5.4 North America Liposomal Amphoteracin B Market Facts & Figures by Country
5.4.1 North America Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
5.4.2 North America Liposomal Amphoteracin B Sales by Country (2021-2032)
5.4.3 North America Liposomal Amphoteracin B Revenue by Country (2021-2032)
5.4.4 United States
5.4.5 Canada
5.5 Europe Liposomal Amphoteracin B Market Facts & Figures by Country
5.5.1 Europe Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
5.5.2 Europe Liposomal Amphoteracin B Sales by Country (2021-2032)
5.5.3 Europe Liposomal Amphoteracin B Revenue by Country (2021-2032)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Liposomal Amphoteracin B Market Facts & Figures by Country
5.6.1 Asia Pacific Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
5.6.2 Asia Pacific Liposomal Amphoteracin B Sales by Country (2021-2032)
5.6.3 Asia Pacific Liposomal Amphoteracin B Revenue by Country (2021-2032)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Liposomal Amphoteracin B Market Facts & Figures by Country
5.7.1 South America Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
5.7.2 South America Liposomal Amphoteracin B Sales by Country (2021-2032)
5.7.3 South America Liposomal Amphoteracin B Revenue by Country (2021-2032)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Liposomal Amphoteracin B Market Facts & Figures by Country
5.8.1 Middle East and Africa Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa Liposomal Amphoteracin B Sales by Country (2021-2032)
5.8.3 Middle East and Africa Liposomal Amphoteracin B Revenue by Country (2021-2032)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Liposomal Amphoteracin B Sales by Type (2021-2032)
6.1.1 Global Liposomal Amphoteracin B Sales by Type (2021-2032) & (K Units)
6.1.2 Global Liposomal Amphoteracin B Sales Market Share by Type (2021-2032)
6.2 Global Liposomal Amphoteracin B Revenue by Type (2021-2032)
6.2.1 Global Liposomal Amphoteracin B Sales by Type (2021-2032) & (US$ Million)
6.2.2 Global Liposomal Amphoteracin B Revenue Market Share by Type (2021-2032)
6.3 Global Liposomal Amphoteracin B Price by Type (2021-2032)
7 Segment by Application
7.1 Global Liposomal Amphoteracin B Sales by Application (2021-2032)
7.1.1 Global Liposomal Amphoteracin B Sales by Application (2021-2032) & (K Units)
7.1.2 Global Liposomal Amphoteracin B Sales Market Share by Application (2021-2032)
7.2 Global Liposomal Amphoteracin B Revenue by Application (2021-2032)
7.2.1 Global Liposomal Amphoteracin B Sales by Application (2021-2032) & (US$ Million)
7.2.2 Global Liposomal Amphoteracin B Revenue Market Share by Application (2021-2032)
7.3 Global Liposomal Amphoteracin B Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Liposomal Amphoteracin B Value Chain Analysis
8.1.1 Liposomal Amphoteracin B Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Liposomal Amphoteracin B Production Mode & Process
8.2 Liposomal Amphoteracin B Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Liposomal Amphoteracin B Distributors
8.2.3 Liposomal Amphoteracin B Customers
9 Global Liposomal Amphoteracin B Analyzing Market Dynamics
9.1 Liposomal Amphoteracin B Industry Trends
9.2 Liposomal Amphoteracin B Industry Drivers
9.3 Liposomal Amphoteracin B Industry Opportunities and Challenges
9.4 Liposomal Amphoteracin B Industry Restraints
10 Report Conclusion
11 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Liposomal Amphoteracin B Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Liposomal Amphoteracin B Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Liposomal Amphoteracin B Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Liposomal Amphoteracin B Revenue of Manufacturers (2021-2026)
Table 9. Global Liposomal Amphoteracin B Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Liposomal Amphoteracin B Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Liposomal Amphoteracin B Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Liposomal Amphoteracin B, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Liposomal Amphoteracin B, Product Type & Application
Table 14. Global Liposomal Amphoteracin B Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Liposomal Amphoteracin B by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Gilead Sciences Company Information
Table 19. Gilead Sciences Business Overview
Table 20. Gilead Sciences Liposomal Amphoteracin B Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Gilead Sciences Liposomal Amphoteracin B Product Portfolio
Table 22. Gilead Sciences Recent Developments
Table 23. Cipla Company Information
Table 24. Cipla Business Overview
Table 25. Cipla Liposomal Amphoteracin B Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Cipla Liposomal Amphoteracin B Product Portfolio
Table 27. Cipla Recent Developments
Table 28. Global Liposomal Amphoteracin B Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 29. Global Liposomal Amphoteracin B Sales by Region (2021-2026) & (K Units)
Table 30. Global Liposomal Amphoteracin B Sales Market Share by Region (2021-2026)
Table 31. Global Liposomal Amphoteracin B Sales by Region (2027-2032) & (K Units)
Table 32. Global Liposomal Amphoteracin B Sales Market Share by Region (2027-2032)
Table 33. Global Liposomal Amphoteracin B Revenue by Region (2021-2026) & (US$ Million)
Table 34. Global Liposomal Amphoteracin B Revenue Market Share by Region (2021-2026)
Table 35. Global Liposomal Amphoteracin B Revenue by Region (2027-2032) & (US$ Million)
Table 36. Global Liposomal Amphoteracin B Revenue Market Share by Region (2027-2032)
Table 37. North America Liposomal Amphoteracin B Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 38. North America Liposomal Amphoteracin B Sales by Country (2021-2026) & (K Units)
Table 39. North America Liposomal Amphoteracin B Sales by Country (2027-2032) & (K Units)
Table 40. North America Liposomal Amphoteracin B Revenue by Country (2021-2026) & (US$ Million)
Table 41. North America Liposomal Amphoteracin B Revenue by Country (2027-2032) & (US$ Million)
Table 42. Europe Liposomal Amphoteracin B Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Europe Liposomal Amphoteracin B Sales by Country (2021-2026) & (K Units)
Table 44. Europe Liposomal Amphoteracin B Sales by Country (2027-2032) & (K Units)
Table 45. Europe Liposomal Amphoteracin B Revenue by Country (2021-2026) & (US$ Million)
Table 46. Europe Liposomal Amphoteracin B Revenue by Country (2027-2032) & (US$ Million)
Table 47. Asia Pacific Liposomal Amphoteracin B Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 48. Asia Pacific Liposomal Amphoteracin B Sales by Country (2021-2026) & (K Units)
Table 49. Asia Pacific Liposomal Amphoteracin B Sales by Country (2027-2032) & (K Units)
Table 50. Asia Pacific Liposomal Amphoteracin B Revenue by Country (2021-2026) & (US$ Million)
Table 51. Asia Pacific Liposomal Amphoteracin B Revenue by Country (2027-2032) & (US$ Million)
Table 52. South America Liposomal Amphoteracin B Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 53. South America Liposomal Amphoteracin B Sales by Country (2021-2026) & (K Units)
Table 54. South America Liposomal Amphoteracin B Sales by Country (2027-2032) & (K Units)
Table 55. South America Liposomal Amphoteracin B Revenue by Country (2021-2026) & (US$ Million)
Table 56. South America Liposomal Amphoteracin B Revenue by Country (2027-2032) & (US$ Million)
Table 57. Middle East and Africa Liposomal Amphoteracin B Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 58. Middle East and Africa Liposomal Amphoteracin B Sales by Country (2021-2026) & (K Units)
Table 59. Middle East and Africa Liposomal Amphoteracin B Sales by Country (2027-2032) & (K Units)
Table 60. Middle East and Africa Liposomal Amphoteracin B Revenue by Country (2021-2026) & (US$ Million)
Table 61. Middle East and Africa Liposomal Amphoteracin B Revenue by Country (2027-2032) & (US$ Million)
Table 62. Global Liposomal Amphoteracin B Sales by Type (2021-2026) & (K Units)
Table 63. Global Liposomal Amphoteracin B Sales by Type (2027-2032) & (K Units)
Table 64. Global Liposomal Amphoteracin B Sales Market Share by Type (2021-2026)
Table 65. Global Liposomal Amphoteracin B Sales Market Share by Type (2027-2032)
Table 66. Global Liposomal Amphoteracin B Revenue by Type (2021-2026) & (US$ Million)
Table 67. Global Liposomal Amphoteracin B Revenue by Type (2027-2032) & (US$ Million)
Table 68. Global Liposomal Amphoteracin B Revenue Market Share by Type (2021-2026)
Table 69. Global Liposomal Amphoteracin B Revenue Market Share by Type (2027-2032)
Table 70. Global Liposomal Amphoteracin B Price by Type (2021-2026) & (US$/Unit)
Table 71. Global Liposomal Amphoteracin B Price by Type (2027-2032) & (US$/Unit)
Table 72. Global Liposomal Amphoteracin B Sales by Application (2021-2026) & (K Units)
Table 73. Global Liposomal Amphoteracin B Sales by Application (2027-2032) & (K Units)
Table 74. Global Liposomal Amphoteracin B Sales Market Share by Application (2021-2026)
Table 75. Global Liposomal Amphoteracin B Sales Market Share by Application (2027-2032)
Table 76. Global Liposomal Amphoteracin B Revenue by Application (2021-2026) & (US$ Million)
Table 77. Global Liposomal Amphoteracin B Revenue by Application (2027-2032) & (US$ Million)
Table 78. Global Liposomal Amphoteracin B Revenue Market Share by Application (2021-2026)
Table 79. Global Liposomal Amphoteracin B Revenue Market Share by Application (2027-2032)
Table 80. Global Liposomal Amphoteracin B Price by Application (2021-2026) & (US$/Unit)
Table 81. Global Liposomal Amphoteracin B Price by Application (2027-2032) & (US$/Unit)
Table 82. Key Raw Materials
Table 83. Raw Materials Key Suppliers
Table 84. Liposomal Amphoteracin B Distributors List
Table 85. Liposomal Amphoteracin B Customers List
Table 86. Liposomal Amphoteracin B Industry Trends
Table 87. Liposomal Amphoteracin B Industry Drivers
Table 88. Liposomal Amphoteracin B Industry Restraints
Table 89. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Liposomal Amphoteracin B Product Image
Figure 5. Global Liposomal Amphoteracin B Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Liposomal Amphoteracin B Market Size (2021-2032) & (US$ Million)
Figure 7. Global Liposomal Amphoteracin B Sales (2021-2032) & (K Units)
Figure 8. Global Liposomal Amphoteracin B Average Price (US$/Unit) & (2021-2032)
Figure 9. 25mg Product Image
Figure 10. 50mg Product Image
Figure 11. Hospital Product Image
Figure 12. Pharmacy Product Image
Figure 13. Global Liposomal Amphoteracin B Revenue Share by Manufacturers in 2025
Figure 14. Global Manufacturers of Liposomal Amphoteracin B, Manufacturing Sites & Headquarters
Figure 15. Global Top 5 and 10 Liposomal Amphoteracin B Players Market Share by Revenue in 2025
Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 17. Global Liposomal Amphoteracin B Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 18. Global Liposomal Amphoteracin B Sales by Region in 2025
Figure 19. Global Liposomal Amphoteracin B Revenue by Region in 2025
Figure 20. North America Liposomal Amphoteracin B Market Size by Country in 2025
Figure 21. North America Liposomal Amphoteracin B Sales Market Share by Country (2021-2032)
Figure 22. North America Liposomal Amphoteracin B Revenue Market Share by Country (2021-2032)
Figure 23. United States Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 24. Canada Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 25. Europe Liposomal Amphoteracin B Market Size by Country in 2025
Figure 26. Europe Liposomal Amphoteracin B Sales Market Share by Country (2021-2032)
Figure 27. Europe Liposomal Amphoteracin B Revenue Market Share by Country (2021-2032)
Figure 28. Germany Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. France Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. U.K. Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 31. Italy Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 32. Netherlands Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. Nordic Countries Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. Asia Pacific Liposomal Amphoteracin B Market Size by Country in 2025
Figure 35. Asia Pacific Liposomal Amphoteracin B Sales Market Share by Country (2021-2032)
Figure 36. Asia Pacific Liposomal Amphoteracin B Revenue Market Share by Country (2021-2032)
Figure 37. China Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Japan Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. South Korea Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. India Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Australia Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. China Taiwan Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Southeast Asia Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. Southeast Asia Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. South America Liposomal Amphoteracin B Market Size by Country in 2025
Figure 46. South America Liposomal Amphoteracin B Sales Market Share by Country (2021-2032)
Figure 47. South America Liposomal Amphoteracin B Revenue Market Share by Country (2021-2032)
Figure 48. Mexico Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Brazil Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Argentina Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Middle East and Africa Liposomal Amphoteracin B Market Size by Country in 2025
Figure 52. Middle East and Africa Liposomal Amphoteracin B Sales Market Share by Country (2021-2032)
Figure 53. Middle East and Africa Liposomal Amphoteracin B Revenue Market Share by Country (2021-2032)
Figure 54. Turkey Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 55. Saudi Arabia Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 56. UAE Liposomal Amphoteracin B Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. Global Liposomal Amphoteracin B Sales Market Share by Type (2021-2032)
Figure 58. Global Liposomal Amphoteracin B Revenue Market Share by Type (2021-2032)
Figure 59. Global Liposomal Amphoteracin B Price (US$/Unit) by Type (2021-2032)
Figure 60. Global Liposomal Amphoteracin B Sales Market Share by Application (2021-2032)
Figure 61. Global Liposomal Amphoteracin B Revenue Market Share by Application (2021-2032)
Figure 62. Global Liposomal Amphoteracin B Price (US$/Unit) by Application (2021-2032)
Figure 63. Liposomal Amphoteracin B Value Chain
Figure 64. Liposomal Amphoteracin B Production Mode & Process
Figure 65. Direct Comparison with Distribution Share
Figure 66. Distributors Profiles
Figure 67. Liposomal Amphoteracin B Industry Opportunities and Challenges
提及公司
Gilead SciencesCipla
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們